- ASCO® 2024
- Yale Cancer Answers
- ASH CME Series
- Smilow Shares with Primary Care
- Grand Rounds
- Head and Neck
- Gynecologic
- Benign Hematology
- Breast
- GI
- Lung
- GU
- Hematologic Oncology
- Brain
- Cancer Screening
- DEI (Diversity, Equity and Inclusion)
- 2021 ASH Highlights
- General Events
- Events
Playback speed
10 seconds
Gynecologic Oncology Updates: Expert Perspective on Key Trial Findings
By
Yale Cancer Center
FEATURING
Elena Ratner
By
Yale Cancer Center
FEATURING
Elena Ratner
216 views
October 17, 2024
Chapters
Low-Grade Ovarian Cancer Advancements
00:00
PARP Inhibitors & ctDNA Studies in Ovarian Cancer
02:03
Advanced Ovarian Cancer: Yale Ixabepilone Trial
03:45
RUBY Trial: Endometrial Cancer & Dostarlimab Approval
04:37
GOG-3041: Durvalumab & PARP Inhibitors in Endometrial Cancer
06:38
PARP Inhibitors' Role in Uterine & Cervical Cancer
07:31
Surgical Trials & Mirvetuximab Use in Ovarian & Endometrial Cancer
09:21
Comments 0
Login to view comments.
Click here to Login
ASCO® 2024